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Abstract
Although tamoxifen treatment is associated with improved survival in patients with estrogen receptor (ER)–positive
breast tumors, resistance remains an important clinical obstacle. Signaling through growth factor signaling path-
ways, in particular through receptor tyrosine kinases, has been demonstrated to confer tamoxifen resistance in an
estradiol-independent manner. The Ron receptor tyrosine kinase, a member of the c-Met family of receptors, is
expressed in a number of human epithelial tumors, and elevated expression of Ron is associated with poor prog-
nosis in women with breast cancer. In this report, we evaluated the role of Ron receptor activation in conferring
resistance to tamoxifen in human and murine breast cancer cell lines. Activation of Ron by its ligand, hepatocyte
growth factor–like protein (HGFL) was associated with partial rescue from tamoxifen-induced growth inhibition in
Ron-expressing cell lines. Western analysis revealed that treatment of the T47D human breast cancer cell line with
tamoxifen and HGFL was associated with increased phosphorylation of mitogen-activated protein kinase (MAPK)
1/2 and phosphorylation of serine residue 118 of ER. Expression of ER-dependent genes was increased in cells
treated with tamoxifen and HGFL by quantitative reverse transcription–polymerase chain reaction. All of these ef-
fects were inhibited by treatment with either a Ron-neutralizing antibody or a MEK1 inhibitor, suggesting the spec-
ificity of the effect to Ron, and the involvement of the MAPK 1/2 signaling pathway. In summary, these results
illustrate a novel connection between the Ron receptor tyrosine kinase and an important mechanism of tamoxifen
resistance in breast cancer.
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Introduction
Among women in the United States, breast cancer is the most com-
mon cancer diagnosed. It is second only to lung cancer in mortality,
with 180,000 new cases each year and 40,000 deaths. Treatment
with the selective estrogen receptor modulator tamoxifen has been
shown to significantly reduce recurrence rates in women diagnosed
with estrogen receptor alpha (ER)–positive breast tumors [1]. How-
ever, subsets of patients with ER-positive tumors do not respond to
tamoxifen, or recur despite tamoxifen therapy, indicating tumor resis-
tance to this treatment and a need to identify aggressive ER-positive
tumors [2]. Several mechanisms have been implicated in tamoxifen
resistance, including overexpression of coactivator proteins, such as
amplified in breast cancer 1 [3], decreased expression of corepressor
proteins, such as nuclear receptor corepressor [4], and activation of
growth factor pathways leading to ligand-independent ER activation
[5,6]. Interestingly, most tamoxifen-resistant tumors retain ER posi-
tivity [1].
Ligand-independent ER activation through growth factor signal-
ing has been investigated as a mechanism of tamoxifen resistance.
Phosphorylation of serine residue 118, located in the activation fac-
tor 1 (AF1) domain of ER, is known to result in the transcription of
ER-dependent genes. This phosphorylation occurs not only because
Abbreviations: EGFR, epidermal growth factor receptor; ER, estrogen receptor alpha;
HGFL, hepatocyte growth factor–like protein; MAPK, mitogen-activated protein kinase
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of estradiol binding to ER but also occurs by mitogen-activated pro-
tein kinase (MAPK) 1/2 activation, independent of estradiol [1].
When bound to ER, tamoxifen alters the binding and recruitment
of coactivators to the AF2 domain of ER, but does not inhibit the
activity of the AF1 domain, and upregulates transcriptional activity
of ER through AF1 signaling in some breast cancer cell lines [7,8].
Activation of the receptor tyrosine kinases epidermal growth factor
receptor (EGFR) and Her2 has been shown to result in the phos-
phorylation of serine 118 through MAPK1 signaling, leading to resis-
tance to tamoxifen in human breast cancer cell lines [7,9]. Of seven
genes identified that conferred tamoxifen resistance in a retroviral
transfer of complementary DNA (cDNA) libraries into breast cancer
cells, four were receptor tyrosine kinases, and the remaining three were
ligands for these receptors, underscoring the potential importance of
this mechanism of tamoxifen resistance in human disease [10].
Ron is a receptor tyrosine kinase related to the c-Met receptor that
has been identified as an oncogene in the development and growth of
human epithelial tumors [11]. In cell lines, wild-type Ron overex-
pression is associated with the induction of oncogenic properties, in-
cluding malignant transformation, proliferation, and migration [12].
Overexpression of Ron in transgenic mouse models of both lung and
breast cancers is associated with tumorigenesis in both organs [13,14].
In addition, Ron is known to be upregulated in a number of human
epithelial cancers, including breast, lung, stomach, colon, pancreas,
and prostate [15]. Whereas Ron is expressed at low levels in normal
breast epithelium, it is highly expressed in approximately 50% of hu-
man breast cancers [16].
The expression of Ron in human breast tumors has been associated
with poor prognosis in a number of analyses. In node-negative early
stage breast cancers, Ron expression is associated with a two-fold in-
crease in tumor recurrence compared with Ron-negative tumors [17].
Breast tumors expressing the genes for Ron, its ligand, hepatocyte
growth factor–like protein (HGFL), and a membrane-bound serine
protease that cleaves HGFL to its active form, are associated with
worse disease-free and overall survival and increased metastases com-
pared with tumors that do not express this three-gene combination
[18]. Finally, in an examination of gene expression patterns from
189 breast tumors, Ron expression correlated with ER-positivity [19].
With this background, we hypothesized that Ron activation by
HGFL may confer tamoxifen resistance in breast cancer cells. We
present evidence that treatment of Ron-expressing human and mu-
rine breast cancer cell lines with HGFL is associated with rescue from
tamoxifen-mediated growth inhibition. This effect is associated with
MAPK-mediated phosphorylation of serine 118 of ER and the in-
creased expression of genes associated with ER activation in the pres-
ence of tamoxifen. Our findings identify a novel link between the
Ron receptor tyrosine kinase and an important mechanism of tamox-
ifen resistance in breast cancer.
Materials and Methods
Reagents and Plasmids
Antibody to Ron (C-20, rabbit polyclonal) was purchased from
Santa Cruz Biotechnology (Santa Cruz, CA). Antibody to ERα (6F11,
mouse monoclonal) was purchased from Vector Laboratories (Burlin-
game, CA). Antibodies to total MAPK1/2 (06-182, rabbit polyclonal)
were purchased from Millipore (Billerica, MA). Antibodies to phos-
phorylated p42/44 MAPK 1/2 (9106, mouse monoclonal) and ERα
(S118) were purchased from Cell Signaling (Danvers, MA). Anti-
bodies to pRon (Y1238/Y1239) were purchased from R&D Systems
(Minneapolis MN). Plasmid containing the gene for the full-length
wild-type human Ron was cloned into PCI-Neo vector, purchased
from Promega (Madison, WI). 4-Hydroxy-tamoxifen was purchased
from Sigma (St Louis, MO) and resuspended in 100% ethanol as
per the manufacturer’s instructions. Activated HGFL protein (re-
combinant human MSP, Cys 672 Ala) and mouse and human Ron-
neutralizing antibodies were purchased from R&D Systems and were
resuspended in phospho-buffered saline with 0.1% bovine serum
albumin as per the manufacturer’s instructions. PD98059 was pur-
chased from Cell Signaling, and PP2 was from Calbiochem (San
Diego, CA); both were resuspended in dimethyl sulfoxide as per
the manufacturer’s instructions. Cell culture reagents, including me-
dia, serum, and antibiotic additives, were purchased from Invitrogen
(Carlsbad, CA).
Cell Culture and Transfection
MCF-7 and T47D cells were purchased from American Type Cul-
ture Collection (Manassas, VA). The R7 cell line is a murine mammary
epithelial tumor cell line established from a mammary tumor from a
transgenic MMTV-Ron mouse. This transgenic mouse model has been
described previously [13]. Cell lines were maintained in RPMI, supple-
mented by 10% fetal bovine serum and 1% penicillin-streptomycin.
Transfection of PCI-Neo Ron, PCI-Neo empty vector, ERE-Firefly lu-
ciferase, and CMV-Renilla luciferase was carried out using Lipofec-
tamine 2000 (Invitrogen) as per the manufacturer’s instructions.
Crystal Violet Measurement of Cell Number
Cells were trypsinized, counted, and plated in equal numbers in
24-well tissue culture plates in maintenance media. After 24 hours,
cells were treated in quadruplicate with specified reagents or vehicle
controls in a maintenance medium. After 120 hours of treatment, the
medium was removed, and cells were rinsed with sterile phospho-
buffered saline, fixed in 4% formaldehyde, and stained with 0.1%
crystal violet solution in 25% methanol. Extra crystal violet solution
was then removed by rinsing repeated with water. After drying, 0.2%
Triton X-100 detergent was added to all wells and gently rocked for
30 minutes. The resulting supernatant underwent photometric analy-
sis on a monochromator (SynergyMx plate reader; BioTek Instru-
ments, Winooski, VT) at an absorbance of 590 nm.
Luciferase Reporter Assay
Twenty-four hours before transfection, T47D cells were switched
to phenol red–free Dulbecco modified Eagle medium (DMEM) con-
taining 5% charcoal-stripped serum. Transfection of plasmids was
carried out with Lipofectamine 2000 reagent as per the manufac-
turer’s protocol. Cells were treated with HGFL, estradiol, or the Ron
neutralizing antibody 24 hours after transfection, and cell lysates were
collected and assayed 18 hours later. Luciferase assay was performed
using the Dual-Luciferase Assay System (Promega) as per the manu-
facturer’s instructions. Each sample was run in duplicate and averaged,
and renilla-luciferase was used to control for transfection efficiency be-
tween samples.
Real-time Polymerase Chain Reaction Analysis
Cells were plated in maintenance a medium for at least 24 hours.
The medium was then changed to phenol red–free DMEM contain-
ing 5% charcoal-stripped fetal bovine serum for 24 hours. Cells were
Neoplasia Vol. 12, No. 8, 2010 Ron Receptor Activation and Tamoxifen Resistance McClaine et al. 651
then treated with tamoxifen, HGFL, the Ron-neutralizing antibody,
or PD98059, along with vehicle controls, for an additional 24 hours
in phenol red–free DMEM with 5% charcoal-stripped fetal bovine
serum. Cells were rinsed in phospho-buffered saline and lysed with
TRIzol reagent (Invitrogen). RNA was isolated from TRIzol reagent
solutions by chloroform-isopropanol preparation. DNA was prepared
from isolated RNA using High-Capacity cDNA Reverse Transcrip-
tase Kit (Applied Biosystems, Foster City, CA) as per the manufac-
turer’s instructions. Experimental plates consisted of cDNA samples
from three independently treated and independently isolated RNA
samples for each treatment group, plated in duplicate. The sequence
for the forward and reverse primers for cyclin D1 is 5′-GTT CGT
GGC CTC TAA GAT-3′ and 5′-ACT CTG GAA AGA AAG TGC-
3′, respectively. The expression of these genes was normalized to the
expression of β-glucuronidase (GUS: forward, 5′-TTG AGA ACT
GGT ATA AGA CGC ATC AG-3′ and reverse, 5′-TCT GGT
ACT CCT CAC TGA ACA TGC-3′). Real-time polymerase chain
reaction was performed using SYBR green in 96-well plates read with
7900HT Fast Real-time PCR/Sequence Detection Systems (Applied
Biosystems). Graphic results represent the relative change in the mes-
senger RNA (mRNA) expression compared with vehicle for each
treatment group.
Immunoblot Analysis
Cells were plated and grown to near confluence in maintenance
media. The media was then changed to phenol red–free DMEM con-
taining 5% charcoal-stripped fetal bovine serum for 24 hours. Cells
were then treated with tamoxifen, the Ron-neutralizing antibody or
PD98059, along with vehicle controls, for 20 minutes, followed by
treatment with HGFL and estradiol for an additional 20 minutes.
Whole-cell lysates were prepared in radioimmunoprecipitation assay
buffer (20 mM Tris, 150 mM sodium chloride, 2 mM EDTA, 0.1%
SDS, 1% Triton X-100, 0.5% sodium deoxycholate, and 10% glyc-
erol), supplemented with complete protease inhibitor tablets (Roche,
Palo Alto, CA) and HALT phosphatase inhibitors (Pierce, Rockford,
IL). Protein concentrations were determined by Micro BCA Protein
Assays (Pierce). Lysates were then boiled for 10 minutes in buffer con-
taining β-mercaptoethanol and were separated by SDS-PAGE. Im-
munoblot analysis was carried out according to standard procedures
on polyvinylidene fluoride membrane, with enhanced chemilumines-
cence detection (GE Healthcare, Piscataway, NJ). Densitometry was
performed on NIH Image J analysis software.
Statistical Analysis
Data shown are indicative of at least three independent experiments.
Results are expressed as mean ± SEM. For multiple comparisons,
one-way analysis of variance (ANOVA) was performed, followed
by Tukey posttest (for parametric data). For Ron knockdown study,
a two-way ANOVA was performed. For all analyses, P < .05 was con-
sidered significant.
Results
Stimulation of Endogenous Ron in Breast Cancer Cell Lines
Enhances Survival in the Presence of Tamoxifen
Correlative evidence has demonstrated that Ron and ER are coex-
pressed in a subset of tamoxifen-resistant breast cancers. Therefore,
to test whether Ron signaling is a factor in regulating the resistance of
breast cancer cells to tamoxifen, the coordinate expression of Ron and
ER was first examined by Western analysis in two ER-positive human
breast cancer cell lines (MCF-7 and T47D), an ER-negative cell line
(MDA-MB-231), as well as in murine mammary tumor cells (R7 cells)
derived from transgenic mice selectively overexpressing Ron in the
breast epithelium [13,20]. The Ron receptor was highly expressed in
T47D cells with limited expression in MDA-MB-231 and low to un-
detectable levels of Ron observed in MCF-7 cells (Figure 1A). Simi-
larly, high Ron expression was observed in the R7 cells (Figure 1B).
The antibody used to detect Ron in these studies was generated against
peptide sequences corresponding to human Ron, but cross-reaction
with the murine Ron homolog was observed, although the detection
of Ron in mice is less efficient than that observed for human Ron.
Moreover, ER expression was also observed in the R7 murine breast
cancer cells (Figure 1B).
Next, to examine the tamoxifen sensitivity of ER-positive cell lines,
T47D, MCF-7, and R7 cells were plated in the presence or absence of
increasing concentrations of tamoxifen. Crystal violet assays were used
to measure the cytotoxic effect of tamoxifen in all three breast cancer
cell lines. The cytotoxic effect of tamoxifen treatment occurred in a
dose-dependent fashion (Figure 2, A–C ). The median lethal dose for
R7 cells and T47D cells was approximately 3.5 to 4 μM, whereas
MCF-7 cells had a median lethal dose of 2.5 μM, which is similar
to concentrations reported previously for MCF-7 cells [5,20,21]. To
examine the outcome of endogenous Ron stimulation during tamox-
ifen treatment, T47D and R7 cells, both of which express high levels of
endogenous Ron, were treated with tamoxifen alone, tamoxifen and
Ron ligand (HGFL), or vehicle alone. HGFL treatment partially res-
cued cells from the cytotoxic effects of tamoxifen (Figure 2, D and E ).
Specifically, treatment of R7 cells with tamoxifen and a physiologic dose
of HGFL (100 ng/ml) [22,23] was associated with a 400% increase in
the number of R7 cells compared with tamoxifen treatment alone. Sim-
ilarly, in T47D cells, a dose of 50 ng/ml of HGFLwas associated with a
12.5% increase in the number of T47D cells; increases of up to 30%
were observed with a dose of 100 ng/ml (data not shown). For both R7
and T47D cells, treatment with all doses of HGFL was associated with
a significant increase in the number of cells compared with tamoxifen
treatment alone. Conversely, HGFL treatment of MCF-7 cells, which
demonstrate low levels of Ron expression, had no significant effect
on tamoxifen-treated cells (Figure 2F). For all three cell lines, the total
Figure 1. Ron and ER are expressed in human and murine breast
cancer cell lines. Expression of ER and Ron was examined by West-
ern analysis of cell lysates generated from the human breast cancer
cell lines MCF-7, MDA-MB-231, and T47D (A) and the murine epi-
thelial breast cancer line R7 (B). T47D cells express high levels of
human Ron compared with MDA-MB-231 cells and MCF-7 cells.
R7 cells express high levels of murine Ron.
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cell number was significantly decreased with tamoxifen and tamoxifen
plus HGFL treatment, compared with vehicle treatment. Importantly,
treatment with HGFL alone, at any dose, did not independently in-
crease the number of T47D, MCF-7, or R7 cells during this experi-
ment (data not shown).
Exogenous Ron Expression Confers Tamoxifen Resistance
To confirm the specific requirement for the Ron receptor to rescue
cells from tamoxifen-induced cytotoxicity, we transiently transfected
MCF-7 cells, which express low endogenous levels of this receptor,
with a Ron expression plasmid or control vector. Our transient trans-
fections resulted in approximately 40% of cells being transduced
with exogenous expression of Ron that was maintained for at least
120 hours during these experiments (data not shown). Ron expres-
sion was confirmed by Western analyses. Mock-transfected (MT)
MCF-7 cells and cells transfected with empty vector (PCI-Neo EV)
served as controls. Robust Ron expression was observed after transfec-
tion with a Ron-expressing plasmid (PCI-Neo Ron) compared with
controls (Figure 3A). Consistently, treatment of the MT MCF-7,
PCI-Neo EV MCF-7, and PCI-Neo Ron MCF-7 cells with tamoxifen
was associated with dose-dependent cytotoxicity similar to that ob-
served in wild-type MCF-7 cells (Figure 3, B–D). Graphs represent
relative absorbance values normalized to the vehicle-treated cells for
each transfection group. Importantly, treatment with HGFL was asso-
ciated with a 50% increase in the number of PCI-Neo Ron MCF-7
cells at both 3 and 4 μM concentrations of tamoxifen (Figure 3D).
This effect was not observed in MT MCF-7 cells (Figure 3C ) or in
PCI-Neo EV MCF-7 cells (Figure 3B).
Knockdown of Ron in a Breast Cancer Cell Line Enhances
Tamoxifen Sensitivity
Next, to determine whether knockdown of Ron could sensitize
breast cancer cells to tamoxifen, we transduced T47D cells with short
hairpin RNA constructs targeting Ron mRNA (T47D RonKD). The
efficacy of the Ron knockdown on protein levels was approximately
50% to 70% (Figure 4A). These cells were then treated with a con-
centration range of tamoxifen in complete medium containing HGFL,
and its effects on the cell number were assessed by crystal violet stain-
ing. T47D RonKD cells were more sensitive to tamoxifen over the
entire concentration range given (0.5-8 μM; Figure 4B). The con-
centrations of tamoxifen metabolites detected in breast tissue from
tamoxifen-treated patients are reported to fall between 0.67 and
14 μM, suggesting that our treatment doses fall within the physiologic
range [1].
HGFL-Mediated Rescue of Ron-Expressing Breast Cancer
Cells from Tamoxifen Treatment Is Attenuated by Ron or
MAPK Inhibition
Having demonstrated the ability of HGFL treatment to partially
reverse tamoxifen-induced cytotoxicity in T47D and R7 cells, we
next aimed to determine the importance of Ron and Ron-dependent
downstream signaling mechanisms for this protective effect. T47D
and R7 cells were treated with tamoxifen and HGFL, as previously
mentioned, and with mouse or human Ron-neutralizing antibodies
or the MEK1 inhibitor PD98059, at doses that were not indepen-
dently associated with altered cell growth (data not shown). Treat-
ment of T47D cells with 4 μM tamoxifen alone was associated
with approximately 50% reduction in cell number. Concurrent treat-
ment with HGFL leads to an approximately 30% rescue in cell num-
ber, similar to the effect described previously in Figure 2. Addition of
a Ron-neutralizing antibody to HGFL-treated cells reversed the res-
cue effect seen with HGFL alone, resulting in a cell number equiv-
alent to that seen with tamoxifen treatment alone. Similarly, addition
of PD98059 negated the HGFL-mediated rescue to that seen with
tamoxifen treatment alone (Figure 5A). In R7 cells, treatment with
3 μM tamoxifen resulted in a 67% reduction in cell number, and
Figure 2. Stimulation of endogenous Ron in breast cancer cell lines enhances survival in the presence of tamoxifen. Establishment of
the endogenous sensitivity of T47D (A), the murine breast cancer cell line R7 (B), and MCF-7 (C) cells to tamoxifen. Tamoxifen-induced
growth inhibition is reversed by HGFL in T47D cells (D) and R7 cells (E); HGFL does not affect tamoxifen-induced growth arrest in MCF-7
cells (F). Columns represent mean values ± SEM with *P < .05. Each assay was performed in quadruplicate, and the graphs are rep-
resentative of several independent experiments.
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HGFL treatment was associated with a partial reversal of this effect,
as described previously in Figure 2. Treatment with a mouse Ron-
neutralizing antibody essentially reversed the effect of HGFL treat-
ment. Similar results were observed with treatment with the MEK1
inhibitor PD98059 (Figure 5B). Treatment with the MEK1 inhibitor
alone at the doses used in this experiment had no effect on cell number
(data not shown). To determine the possible importance of the non–
receptor tyrosine kinase c-Src as a potential intermediary between Ron
and MAPK activation, we repeated the experiments in the presence
of PP2, a known c-Src inhibitor, at concentrations ranging from 0.1
to 10 μM. This inhibitor has been shown to decrease c-Src activation
in vitro at 10 μM concentration [24]. Treatment of both cell lines with
all concentrations of PP2 was associated with a decrease in overall cell
growth in the presence of tamoxifen and HGFL, similar to the effects
seen with a Ron-neutralizing antibody and MEK1 inhibitor PD98059
(data not shown). However, treatment of R7 and T47D cells with all
concentrations of PP2 was independently associated with a decrease in
cell number during the experiment, suggesting that, although c-Src is
important for the growth of these cell lines, it may not play a role in
the HGFL-mediated rescue from tamoxifen.
Treatment of Ron-Expressing Breast Cancer Cell Lines with
Tamoxifen and HGFL Is Associated with Increased
Phosphorylation of the Serine 118 Residue of ER and
Activation of MAPK
To further evaluate the mechanism by which HGFL may be reg-
ulating resistance to tamoxifen, we performed Western analyses of
T47D cells treated with HGFL, a Ron-neutralizing antibody, and/
or PD98059. Cells were pretreated for 20 minutes with PD98059
(MEK inhibitor) or a Ron-neutralizing antibody, then treated for an
additional 30 minutes with HGFL, and total cell lysates were gener-
ated. This time course is consistent with the previously published lit-
erature on the phosphorylation of ER and MAPK [5]. Figure 6 depicts
a representative Western of whole-cell lysates after each treatment,
which is representative of three independent experiments. HGFL stim-
ulation induced Ron phosphorylation at tyrosine residues 1238/1239,
which are responsible for its kinase activity. We also observed the ac-
tivation (i.e., phosphorylation) of pMAPK (Figure 6) after HGFL.
Ron activation was associated with an increase in the amount of phos-
phorylated ER (pER), which was specifically phosphorylated at ser-
ine 118, per total amount of ER (ER), compared with vehicle. Ron
neutralization reduced the levels of tyrosine-phosphorylated Ron
(pRon) and pMAPK, whereas PD98059 only reduced levels of
pMAPK, suggesting that the actions of HGFL are Ron-specific. How-
ever, both the Ron-neutralizing antibody and PD98059 blocked the
phosphorylation of ER at serine 118, suggesting that Ron activation
and MAPK activity are required for this effect (Figure 6).
Treatment of Ron-Expressing Breast Cancer Cells with
Tamoxifen and HGFL Is Associated with Increased Expression
of ER-Dependent Genes
To further explore themechanisms bywhichHGFLmay be inducing
resistance to tamoxifen, we evaluated the expression of ER-dependent
target genes. To accomplish this, R7 cells were treated with tamoxifen
Figure 3. (A) Ron overexpression in MCF-7 cells leads to HGFL-induced tamoxifen resistance. MCF-7 cells were transfected with PCI-
Neo Ron or with PCI-Neo EV. Increased levels of Ron expression in PCI-Neo Ron cells was confirmed by Western analysis compared
with MT MCF-7 cells and PCI-Neo EV cells. Crystal violet cell growth assays were performed on all three cell lines, with cell growth
normalized to vehicle-treated cells for graphic representation. The tamoxifen-induced growth inhibition of PCI-Neo Ron MCF-7 cells was
reversed by treatment with HGFL (D); this effect was not seen in PCI-Neo EV cells (B) or in MT MCF-7 cells (C). Columns represent mean
values ± SEM with *P < .05. Each assay was performed in quadruplicate, and the graphs are representative of several independent
experiments, with mean values compared with vehicle-treated cells.
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and HGFL, in combination with a mouse Ron-neutralizing antibody
or the MEK1 inhibitor PD98059, in doses that alone did not alter
cell number. HGFL and estradiol alone stimulated cyclinD1 expression
over vehicle treatment, whereas tamoxifen treatment alone did not
(Figure 7A). Cotreatment of HGFL and estradiol did not enhance
cyclin D1 expression over estradiol alone. Treatment of cells with
PD98059 or the Ron-neutralizing antibody alone had no effect on
cyclin D1 expression (data not shown). Interestingly, combined treat-
ment with tamoxifen and HGFL was associated with an expression of
cyclin D1 mRNA similar to that induced by estradiol treatment
(Figure 7A). This induction was approximately 3.5-fold higher than
that observed with tamoxifen treatment alone and was inhibited
by treatment with a Ron-neutralizing antibody or MEK1 inhibition
(Figure 7A).
To better understandwhether Ron activation can affect ER responsive-
ness and, therefore, partially explain changes in ER target gene expression,
we used an estrogen response element–luciferase plasmid (ERE-luc).
HGFL-stimulated luciferase expression in ERE-luc–transfected T47D
cells was approximately 1.8-fold higher than vehicle-treated cells. Fur-
thermore, this stimulation was inhibited by the Ron-neutralizing anti-
body, highlighting the specificity of this effect on Ron (Figure 7B).
Discussion
The selective estrogen receptor modulator tamoxifen has been used
successfully to prevent recurrence of ER-positive breast cancer, signif-
icantly improving disease-free and overall survival. Despite this suc-
cess, a subset of breast cancer patients will recur despite tamoxifen or
other antiestrogen therapy, highlighting the clinical importance of elu-
cidating mechanisms by which breast cancer cells become resistant
to these therapies and devising strategies to overcome this resistance
to further improve outcomes. The activation of ER through growth
factor signaling, independent of estradiol, has been demonstrated to
be an important mechanism of resistance. The receptor tyrosine kinase
Ron is known to be associated with poor prognosis in breast cancer
[17,18]. This association led us to hypothesize that activation of
Ron in breast cancer cells may confer resistance to tamoxifen, leading
to poorer clinical outcomes. Here, we demonstrate that 1) activation of
Ron by its ligand, HGFL, partially reverses tamoxifen-induced cyto-
toxicity in human and mouse breast cancer cell lines, and that this
effect is attenuated with Ron inhibition; 2) activation of Ron is asso-
ciated with phosphorylation of the serine 118 residue of ER through
Figure 5. Ron receptor neutralization or the use of a MEK1 inhibitor
restores tamoxifen sensitivity in breast cancer cell lines treated with
HGFL. The human breast cancer cell line T47D and the murine epi-
thelial breast cancer cell line R7 were treated with tamoxifen, HGFL,
Ron-neutralizing antibody, and/or a MEK1 inhibitor (PD98059) for
120 hours. Cells were then fixed, and cell number was analyzed
by crystal violet assays. HGFL-mediated resistance of T47D (A)
and R7 (B) cells to tamoxifen exposure is inhibited with the inclusion
of both a Ron-neutralizing antibody and a MEK1 inhibitor. Columns
represent mean values ± SEM with *P < .05. Each assay was per-
formed in quadruplicate, and the graphs are representative of sev-
eral independent experiments.
Figure 4. (A) Knockdown of Ron in breast cancer cell lines enhances
tamoxifen sensitivity. Lentivirus-delivered short hairpin RNA to Ron
was transduced into T47D cells. The efficacy of the knockdown on
Ron protein in a polyclonal population of T47D cells is shown. Actin
serves as a loading control. Both the parental and RonKD cells
were treated with increasing concentrations of tamoxifen. (B) After
96 hours of treatment, the cells were fixed and stained with crystal
violet, and cell number was assessed by photometric analysis at
590 nm of the supernatant after dye extraction from stained cells.
Tamoxifen treatment results in a dose-dependent growth inhibition
of parental and RonKD T47D cells. Note, however, that the RonKD
cells were more sensitive to tamoxifen at every dose assessed (n =
4, P < .001, two-way ANOVA).
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activation of MAPK, a pathway that has been implicated in tamoxifen
resistance in other in vitro and in vivo studies; and 3) Ron activation
by HGFL alters the expression of ER-dependent genes in the presence
of tamoxifen.
The validation of Ron as an oncogene in human cancer has been
the focus of many recent investigations [12–15,25]. In vitro, Ron has
been shown to induce malignant transformation, proliferation, and
migration [12]. In vivo, treatment with a specific Ron inhibitor de-
creases the growth rate of human tumor cell xenografts in nude mice
[15]. Importantly, a mammary-directed expression of Ron causes
breast tumor formation in 100% of mice [13]. Ron mediates its ef-
fects through a number of intracellular second messengers and signal-
ing pathways, including Ras-RAF-MAPK 1/2, phosphoinositide-3
kinase–Akt, β-catenin, and nuclear factor-κB [26]. Cross talk be-
tween Ron and other tyrosine kinase receptors such as EGFR has also
been described; this cross talk is associated with increased motility
and malignant transformation in cell lines expressing more than
one receptor [25]. Further work has demonstrated differences in
downstream effects associated with ligand-dependent versus ligand-
independent Ron activation [27]. Specifically, MCF-10A cells trans-
fected with human Ron required HGFL only for proliferation; cells
were able to migrate, spread, and survive in the absence of HGFL,
presumably because of other growth factor signaling or heterodimeri-
zation with other receptors [27]. In our model, HGFL did not induce
additional growth in T47D cells and in the murine breast cancer cell
line, R7 cells, in the presence of serum; however, less cytotoxicity was
seen with HGFL treatment in the presence of tamoxifen, suggesting
that ligand-dependent Ron activation is necessary for the tamoxifen
resistance that we observed. Furthermore, this effect was largely inhib-
ited by treatment with a Ron-neutralizing antibody, suggesting that the
actions of HGFL are limited to a specific interaction with Ron. Feres
et al. [27] also described the importance of the non–receptor tyrosine
kinase c-Src in downstream Ron signaling, for both ligand-dependent
and ligand-independent effects. Treatment of R7 and T47D cells in
our experiments with the c-Src inhibitor PP2 was associated with
growth inhibition, even at very low doses (0.1 μM), which was simi-
lar to previously published results, and underscored the importance of
c-Src signaling to cell proliferation in Ron-expressing cell lines [27].
However, by Western analyses, changes in phosphorylated c-Src were
Figure 6. HGFL stimulation of breast cancer cells leads toMAPK and
ER phosphorylation. T47D cells were treated with a Ron-neutralizing
antibody or MEK1 inhibitor PD98059 for 20 minutes and subse-
quently treated with HGFL for 30 minutes. Cells were then lysed,
and Western analysis was performed. Treatment with HGFL is asso-
ciated with increased phosphorylation Ron and of serine 118 of ER
andMAPK phosphorylation; both the MAPK and ER phosphorylation
events are inhibited by treatment with a Ron-neutralizing antibody or
with a MEK1 inhibitor. However, phosphorylation of Ron is only in-
hibited by the Ron-neutralizing antibody. Pictures depicted are rep-
resentative of three independent experiments.
Figure 7. Transcriptional changes in ER and ER-dependent genes
on HGFL treatment. Real-time reverse transcription–polymerase
chain reaction analysis of ER-dependent mRNA expression was
performed on RNA isolated from murine breast cancer cell lines
after treatment with the indicated agent for 24 hours. (A) Expres-
sion values were normalized to GUS as an internal control, and the
relative expression level of cyclin D1 is illustrated. Treatment with
HGFL (H) in combination with tamoxifen (T) is associated with
changes in expression of cyclin D1. Experiments were performed
in duplicate on three independently treated samples, and relative
expression levels were compared with those of vehicle-treated
cells. All treatments achieve statistical significance (P < .05) com-
pared with vehicle except for tamoxifen alone, H + T + PD98059,
and H + T + neutralizing antibody (Neut Ab). ERE-luciferase plas-
mid was transiently transfected into T47D cells (phenol red–free
medium) and treated with the listed compounds for 16 to 18 hours.
(B) Luciferase expression from four independent replicates was
averaged to create the graph. Columns represent mean values ±
SEM with *P < .05.
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not observed with HGFL or tamoxifen treatment, suggesting that
Ron’s ability to confer tamoxifen resistance is not dependent on c-
Src activation.
The ability of activated receptor tyrosine kinases, other than Ron, to
overcome tamoxifen-induced cytotoxicity in breast cancer cells has been
previously described [1,5,7,11,28]. Serine residue 118, located in AF1
of ER, is known to be a key target of phosphorylation, in carrying out
the activities of ligand-independent and tamoxifen-dependent actions
of ER [29,30]. Mutation of this residue to alanine, rendering it unable
to be phosphorylated, is associated with altered gene expression patterns
in response to both tamoxifen treatment and activation of K-ras, a
downstream regulator of receptor tyrosine kinase activity. However,
transcription patterns associated with estradiol treatment are largely
unaffected by this mutation [7,30]. Treatment with tamoxifen alone
is associated with phosphorylation of serine 118 on ER in breast cancer
cell lines that are both sensitive and resistant to tamoxifen [5,29,31].
Multiple studies have confirmed the ability of EGFR and Her2, when
activated by ligand, to phosphorylate MAPK and serine 118 of ER.
This pathway has been shown to be the mechanism of resistance in
tamoxifen-resistant cell lines expressing Her2 [5], and this resistance
can be partially overcome by treatment with inhibitors of activation,
or antibodies to, Her2 or EGFR [5,9]. Ron, like many other receptor
tyrosine kinases, is known to signal through the MAPK pathway when
activated. Our study also reveals the association between activated Ron
and phosphorylated MAPK and ER in breast cancer cells. The rescue
effect observed with HGFL in the presence of tamoxifen is attenuated
with inhibition of the MAPK pathway, reinforcing the importance of
this mechanism in our experimental system.
The activation of transcription by ER in the nucleus occurs through
multiple mechanisms, including direct binding of the estradiol-ER
complex to EREs in DNA and tethering of the estradiol-ER complex
to DNA by other proteins associated with transcription factor binding
sites such as those of specificity protein 1 or activator protein 1 [30].
The diverse effects of ER activation in various tissues are due to the
complexity of its interactions with DNA through these sites and the
presence or absence of various corepressors or coactivators [1]. To eval-
uate the activation of ER-mediated transcription in our model, we
evaluated the mRNA expression of cyclin D1. The expression of cy-
clin D1, a coactivator in the ER signaling complex, in breast tumors
is associated with poor prognosis in women receiving tamoxifen as ad-
juvant therapy [31,32]. Transcription of the cyclin D1 gene is known
to be activated by ER through tethering to an activator protein 1 site.
Tamoxifen can induce transcription of cyclin D1, although at lower
levels than those achieved with estradiol stimulation [30,33], which
is similar to the effect we observed in the R7 murine breast cancer cell
line. Treatment with Her2 agonist alone induces cyclin D1 expression
in MCF-7 cells, again similar to the effect we observed with HGFL
treatment [5]. Cheng et al. [30] also reported that treatment with a
MAPK pathway inhibitor in the presence of tamoxifen decreased tran-
scription of cyclin D1, again similar to our observations. We further
observed that treatment with both tamoxifen and HGFL had an ad-
ditive effect on cyclin D1 gene expression. Evaluation of another gene,
Wnt1-induced signaling protein-2 (WISP-2), also demonstrated dif-
ferential regulation in response to HGFL and tamoxifen [34] (data
not shown).
To examine the activation of ER-mediated transcription in our
model, we evaluated ERE-driven luciferase expression after Ron acti-
vation. Although HGFL increased the accumulation of the luciferase
protein during the experiment, this result, in itself, does not provide
evidence of a direct Ron-ER connection. However, these data, in combi-
nation with the MAPK-dependent phosphorylation of ER, strengthen
the hypothesis that Ron may be directly affecting ER and, by associa-
tion, tamoxifen resistance. Whereas the mechanism of tamoxifen-,
HGFL-, or other growth factor–induced cyclin D1 expression has not
been completely elucidated [30], our results provide further evidence
that this gene is upregulated in in vitro models of tamoxifen resistance
in breast cancer cells.
In addition to growth factor signaling through MAPK, several other
pathways have been implicated in tamoxifen resistance. Inhibition of
the phosphoinositide-3 kinase–Akt-mTOR signaling pathway, down-
stream of growth factor activation, has been associated with restoration
of sensitivity in tamoxifen-resistant cells [35,36]. Inhibition of c-Src
has been associated with restoration of tamoxifen sensitivity, poten-
tially through facilitating cross talk between receptor tyrosine kinases
and ER in breast cancer cells [37]. Finally, our study did not evaluate
the role of Ron- or MAPK-mediated phosphorylation of AIB1 or other
coactivators of ER signaling, which have also been identified as im-
portant mechanisms of tamoxifen resistance [38]. The involvement
of these pathways in the Ron-mediated tamoxifen resistance that
we observed is beyond the scope of our current study but merits fu-
ture investigation.
In summary, we have described for the first time the ability of the
activated Ron receptor tyrosine kinase to confer resistance to tamox-
ifen in breast cancer cells through a well-characterized pathway. Our
findings illustrate a novel role for Ron in cancer pathology and may
partially explain the poor prognosis associated with Ron expression in
human breast cancer.
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